Korro to Participate in Upcoming Investor Conferences
Korro Bio (Nasdaq: KRRO), a clinical-stage biopharmaceutical company developing RNA-based genetic medicines, has announced its participation in four upcoming investor conferences in December 2024. CEO Ram Aiyar will lead fireside chats at the Piper Sandler Healthcare Conference on December 3 and the Evercore ISI HealthCONx Conference on December 4. The company will also participate in Citi's Global Healthcare Conference on December 5 and the Oppenheimer Movers in Rare Disease Summit on December 12, where Dr. Aiyar will join a panel on RNA Editing. CFO Vineet Agarwal and CMO Dr. Kemi Olugemo will attend various sessions and investor meetings across these events.
Korro Bio (Nasdaq: KRRO), un'azienda biofarmaceutica in fase clinica che sviluppa medicinali genetici basati sull'RNA, ha annunciato la sua partecipazione a quattro conferenze per investitori che si terranno a dicembre 2024. Il CEO Ram Aiyar condurrà conversazioni informali alla Piper Sandler Healthcare Conference il 3 dicembre e all'Evercore ISI HealthCONx Conference il 4 dicembre. L'azienda parteciperà anche alla Citi's Global Healthcare Conference il 5 dicembre e all'Oppenheimer Movers in Rare Disease Summit il 12 dicembre, dove il dott. Aiyar parteciperà a un panel sull'Editing dell'RNA. Il CFO Vineet Agarwal e il CMO Dr. Kemi Olugemo parteciperanno a varie sessioni e incontri con investitori durante questi eventi.
Korro Bio (Nasdaq: KRRO), una empresa biofarmacéutica en etapa clínica que desarrolla medicamentos genéticos basados en RNA, ha anunciado su participación en cuatro conferencias de inversores que se llevarán a cabo en diciembre de 2024. El CEO Ram Aiyar liderará charlas informales en la Piper Sandler Healthcare Conference el 3 de diciembre y en la Evercore ISI HealthCONx Conference el 4 de diciembre. La empresa también participará en la Citi's Global Healthcare Conference el 5 de diciembre y en el Oppenheimer Movers in Rare Disease Summit el 12 de diciembre, donde el Dr. Aiyar se unirá a un panel sobre Edición de RNA. El CFO Vineet Agarwal y la CMO Dra. Kemi Olugemo asistirán a diversas sesiones y reuniones con inversores durante estos eventos.
코로 바이오 (Nasdaq: KRRO)는 RNA 기반 유전자 의약품을 개발하는 임상 단계의 생물의약품 회사로, 2024년 12월에 예정된 네 가지 투자자 컨퍼런스에 참여한다고 발표했습니다. CEO 램 아이야르는 12월 3일 파이퍼 샌들러 헬스케어 컨퍼런스와 12월 4일 에버코어 ISI 헬스콘엑스 컨퍼런스에서 파이어사이드 챗을 이끌 예정입니다. 또한, 회사는 12월 5일 시티의 글로벌 헬스케어 컨퍼런스와 12월 12일 오펜하이머 희귀질환 서밋에도 참석하며, 그곳에서 아이야르 박사가 RNA 편집에 대한 패널에 참여할 것입니다. CFO 비닐 아가르왈과 CMO 케미 올루게모 박사는 이 행사들에서 다양한 세션 및 투자자 회의에 참석할 것입니다.
Korro Bio (Nasdaq: KRRO), une entreprise biopharmaceutique en phase clinique développant des médicaments génétiques basés sur l'ARN, a annoncé sa participation à quatre conférences d'investisseurs prévues en décembre 2024. Le PDG Ram Aiyar animera des discussions informelles lors de la Piper Sandler Healthcare Conference le 3 décembre et de la Evercore ISI HealthCONx Conference le 4 décembre. L'entreprise participera également à la Citi's Global Healthcare Conference le 5 décembre et au Oppenheimer Movers in Rare Disease Summit le 12 décembre, où Dr. Aiyar rejoindra un panel sur l'Édition de l'ARN. Le CFO Vineet Agarwal et la CMO Dr. Kemi Olugemo assisteront à diverses sessions et réunions avec des investisseurs lors de ces événements.
Korro Bio (Nasdaq: KRRO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das RNA-basierte genetische Arzneimittel entwickelt, hat seine Teilnahme an vier bevorstehenden Investorenkonferenzen im Dezember 2024 angekündigt. CEO Ram Aiyar wird am 3. Dezember beim Piper Sandler Healthcare Conference und am 4. Dezember beim Evercore ISI HealthCONx Conference Gespräche führen. Das Unternehmen wird auch an der Citi's Global Healthcare Conference am 5. Dezember und dem Oppenheimer Movers in Rare Disease Summit am 12. Dezember teilnehmen, wo Dr. Aiyar an einem Panel über RNA-Bearbeitung teilnehmen wird. CFO Vineet Agarwal und CMO Dr. Kemi Olugemo werden an verschiedenen Sitzungen und Investorenmeetings während dieser Veranstaltungen teilnehmen.
- None.
- None.
CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that members of management will participate in the following investor conferences:
Piper Sandler 36th Annual Healthcare Conference
Ram Aiyar, Ph.D., Chief Executive Officer and President, will participate in a fireside chat on Tuesday, December 3, 2024, at 4:00 p.m. ET. Vineet Agarwal, Chief Financial Officer, and Kemi Olugemo, M.D., FAAN, Chief Medical Officer, will also participate in 1x1 investor meetings at the conference.
7th Annual Evercore ISI HealthCONx Conference
Dr. Aiyar will participate in a fireside chat on Wednesday, December 4, 2024, at 7:30 a.m. ET. Mr. Agarwal and Dr. Olugemo will also be participating at the conference.
Citi’s 2024 Global Healthcare Conference
Dr. Aiyar, Mr. Agarwal, and Dr. Olugemo will participate in 1x1 investor meetings on Thursday, December 5, 2024.
Oppenheimer Movers in Rare Disease Summit
Dr. Aiyar will participate in a panel titled “Recent Progress on RNA Editing” on Thursday, December 12, 2024, at 3:40 p.m. ET. Mr. Agarwal will also be participating at the conference.
The live webcasts of the Piper Sandler and Evercore fireside chats can be accessed on the “Events & Presentations” page in the Investor section of Korro’s website at www.korrobio.com. Following the presentations, a replay of the event will be available for 30 days.
About Korro
Korro is a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to affect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in Cambridge, Massachusetts. For more information, visit korrobio.com.
Korro Contact Information
Investor & Media Contact
Tim Palmer
IR@korrobio.com
FAQ
What investor conferences will Korro Bio (KRRO) attend in December 2024?
When is Korro Bio's (KRRO) presentation at the Piper Sandler Healthcare Conference?
What is the topic of Korro Bio's (KRRO) panel discussion at the Oppenheimer Summit?
How can investors access Korro Bio's (KRRO) conference presentations?
